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ABSTRACT
ntroduction: Guidelines on rare diseases (RD) are more likely to be produced by groups other than major guideline de-
velopment organisations and therefore the retrieval and dissemination of  guidelines on rare diseases will be more chal-
lenging than for more prevalent conditions. The EU-funded RARE-Bestpractices project includes the development of  
a collection of  guidelines on rare diseases together with a complementary collection of  research recommendations.  The 
basis for development of  this collection is presented.
Methods: To test recall and yield we conducted searches for a sample of  RD reflecting a range of  prevalence: Turner syn-
drome, Huntington’s disease, and Costello syndrome. A systematic search was made of  a range of  sources including databases of  
major guideline producers, PubMed and a number of  portals dedicated to RD together with Google searching. Comparisons were 
made of  the structure and contents of  existing databases of  guidelines and research recommendations.
Results: From sources searched only 15 English language guidelines were retrieved across the 3 test RDs. Searching of  major 
guideline databases was not an effective strategy; the highest number of  relevant results was obtained through Google searches 
and pearl growing, i.e. using one authoritative resource to identify further related resources. Only two databases of  research rec-
ommendations were identified, neither specific to RD.
Discussion: Searches of  current databases of  guidelines and repositories of  information on RD were not effective for retriev-
ing English language RD guidelines, with Google searching proving to be a more successful method. The yield from Google results 
ranged from 4% to 7%, meaning users would need to review a high number of  results to identify relevant material. Therefore, 
there appears to be a need for a database that has high specificity and yield for RD guidelines. 
Conclusions: We have demonstrated that existing resources do not allow for easy identification of  RD guidelines and research 
recommendations. The resources being developed as part of  the RARE-Bestpractices project are intended to meet this need.
KEYWORDS
guidelines, rare diseases, information retrieval, literature searching, search strategies, databases, collection development, 
research recommendations, uncertainties
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INTRODUCTION
Guidelines, defined by the World Health Organization as “systematically developed evidence-based statements which as-
sist providers, recipients and other stakeholders to make informed decisions about appropriate health interventions”, [1] have 
the potential to improve the quality of  healthcare if  they are disseminated to and implemented by their target audience. A 
high-quality guideline can be an expensive investment and some funders consider the prevalence of  a disease as one factor in 
prioritising topics for guideline development. In such a policy environment, rare diseases (RD) may struggle to compete with 
more common diseases and as a result, rare disease guidelines may be more likely to be developed by consensus conferences, 
ad hoc expert groups, charities, or other organisations that may not have equivalent resources to devote to development, dis-
semination and implementation. Databases of  guidelines, such as the Guidelines International Network (G-I-N) database and 
the National Guidelines Clearinghouse, exist to increase the dissemination of  guidelines, but the handful of  RD guidelines may 
be lost in the ‘noise’ of  thousands of  higher-prevalence disease guidelines. As a result of  these factors, RD guidelines are likely 
to require more effort to identify, and are less likely to have adequate resources to support dissemination and implementation, 
than guidelines on common diseases.
The RARE-Bestpractices project funded by the European Union Seventh Framework Programme aims to address this 
disparity and improve the availability of  high-quality best practice guidance, thereby supporting better care for people with 
RD. The project will deliver a sustainable networking platform that will support the exchange of  high-quality knowledge and 
information, principally in the form of  best practice guidelines and research recommendations, in concert with wide-ranging 
but complementary work relating to guideline methodology, value assessment of  orphan medicines, and research dissemina-
tion. Within the RARE-Bestpractices project, work package 4 is led by Healthcare Improvement Scotland with the collabora-
tion of  Karolinska Institutet, Jamarau, Istituto Superiore di Sanità, Universitaetsklinikum Freiburg, and Universiteit Maas-
tricht. A key objective of  this work package is to deliver the information architecture and content for two databases devoted 
to RD knowledge and information, one for guidelines and one for research recommendations. 
The RARE-Bestpractices project was proposed and funded based on the tacit knowledge and experience of  RD special-
ists that RD guidelines and research recommendations require particular effort to retrieve and would benefit from dedicated 
tools and resources to facilitate their dissemination to patients, clinicians and researchers. Previous research has demonstrated 
that health information resources such as Medline and internet search engines perform less well when searching for rare disease 
information as compared to searching for information on common diseases [2-5].  One study tested the use of  Medical Subject 
Headings (MeSH) Concepts versus MeSH Descriptors for improving the precision of  searches for RD topics in PubMed [3]. 
Another study reported on the development of  a new internet search engine for RD diagnostic queries (FindZebra) [4]. To our 
knowledge, no studies have examined information retrieval of  RD guidelines or tested methods of  improving the retrieval of  
RD guidelines. Guidelines are a valuable source of  health information as they systematically identify, appraise, and synthesise 
existing evidence and then translate that evidence into recommendations that are expected to improve outcomes for patients. 
We set out to test recall and yield of  existing databases and optimise search methods for RD guidelines. 
METHODS
We carried out a literature search to assess existing research or practice in rare disease guideline searching or retrieval. 
Medline, Library Information Science and Technology Abstracts (LISTA) and Emerald databases were searched from 2003 
to August 2013 combining ‘rare disease guideline’ and ‘information retrieval’ keyword terms. After sifting the 233 results for 
relevance, four documents were found to pertain to information retrieval in rare diseases, [2-5] although none of  these papers 
concerns the location or provision of  clinical guideline documents. 
In the absence of  a proven approach to guideline retrieval in the field of  rare diseases, the aspects of  the scoping work 
described below were carried out utilising search protocols that have been refined to support the scoping stage of  the develop-
ment of  guidelines and standards in Healthcare Improvement Scotland (HIS). 
The initial search strategy was based on the scoping search protocol for the Scottish Intercollegiate Guideline Network 
(SIGN) [6]. The purpose of  the SIGN scoping search is not to exhaustively retrieve all guidelines but to identify key evidence 
documents which may influence the choice and/or remit of  guideline topics commissioned by the organisation. The protocol 
refers only to large guideline databases such as the Guidelines International Network (G-I-N), National Guidelines Clearing-
house (NGC), and Evidence Search, a database of  guidelines and other resources maintained by the National Institute for 
Health and Care Excellence (NICE).
In order to increase the coverage of  the search, additional searches were conducted with a more comprehensive protocol 
used within HIS to support the development of  clinical standards and quality indicators. This work necessitates an extensive 
search of  resources to identify the maximum number of  international guideline documents which may inform the development 
of  national standards or indicators. The search protocol consists of  30 established guideline producers/databases, additional 
HTA and systematic review resources, primary literature search results (Medline and Embase), and a pragmatic internet 
search consisting of  the subject term plus ‘guideline’ and limited to PDF document type in Google with the first 100 results 
to be checked.
Several RD information portals were also added to the protocol in order to increase sensitivity for RD topics: Orphanet, 
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National Organisation for Rare Disorders (NORD), Eurogentest, Dyscerne, and the Genetic and Rare Diseases Information 
Centre.
To test recall and yield of  existing databases and optimise search methods, we conducted searches for a purposive sample 
of  RD reflecting a range of  prevalence. RD are defined in Europe as having a prevalence of  5 in 10,000 persons. Turner syn-
drome is an example from the high end of  the prevalence spectrum with a prevalence of  1-5 in 10,000. Huntington’s disease has 
a prevalence of  1-9 in 100,000. Costello syndrome is an ultra-rare disease, with approximately 150 cases reported worldwide 
[7].
Search strategies were specific to each individual resource and used both single keywords and more comprehensive search 
strings. The information retrieval technique of  pearl growing was also employed. This refers to the process of  using one au-
thoritative resource to identify further related resources [8] and was proposed as an appropriate search method given that 
background reading and sifting internet search results may introduce the opportunity to identify relevant documents outside 
of  a standardised search protocol.
The inclusion criteria for sifting the RD guidelines search results were: English-language documents published 2003-2013, 
described as guidelines, consensus statements, or best practice statements, AND containing recommendations. In keeping with 
the protocol used for sifting ‘common’ disease guidelines, we excluded documents that were not specific to the disease topic. 
Finally, in addition to testing search strategies and information retrieval, we also conducted comparisons of  the structure 
and contents of  existing databases of  guidelines and research recommendations, in order to identify the unique contribution 
that could be made by databases devoted to RD.
RESULTS
Test searches
The results from the searches for the three sample RD topics were sifted against the inclusion criteria. Tables 1, 2, and 3 
report the recall (total number of  results returned), yield (number and proportion of  results that met inclusion criteria), and 
reasons for exclusion for the three sets of  searches. Most of  the resources used within the existing SIGN and HIS protocols 
for retrieval of  guidelines returned zero results on these RD topics. The tables report in detail results obtained from the seven 
key resources that produced the highest recall and the supplementary search technique of  pearl growing. In total, only four 
guidelines on Turner syndrome were identified, [9-12] eleven guidelines on Huntington’s disease, [13-23] and zero guidelines 
on Costello syndrome.
The two largest guideline-specific databases, G-I-N and NGC, produced a very low yield of  guidelines for the three RD 
topics. Similarly, Evidence Search had a very low yield despite high recall, reflecting the imprecision of  the search functionality 
as well as a low number of  RD guidelines in the database.
The most common reason for exclusion was non-relevance to the clinical topic, indicating a poor specificity for RD topics 
in these resources, apart from Orphanet. Excluding documents in languages other than English meant that, given the very 
small number of  relevant results, a significant number of  guidelines were excluded. For example, Orphanet returned a total of  
eight guidelines for the three topics, but seven of  the eight guidelines were in languages other than English.
For English-language guidelines, the highest number of  relevant results was obtained through Google searches limited to 
PDF documents, and pearl growing.
Table 1. Turner syndrome guidelines retrieved, by source. 
SOURCE RECALL REASONS FOR EXCLUSION YIELD (%)
G-I-N database 2 Not English language 0 (0)
National Guidelines Clearinghouse 71 Not relevant 0 (0)
Orphanet 1 Not English language 0 (0)
Eurogentest 2 1 Not specific to Turner syndrome
1 Not a guideline
0 (0)
PubMed 27 3 Not English language
21 Not relevant
3 (11.1)
Evidence Search (NICE) 393 Not relevant 2 (0.5)
Google pdf  first 100 -- 96 Not relevant 4 (4)
Pearl growing -- -- 0 
Total 596 De-duplication 4 (0.7)
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Table 2. Huntington’s disease guidelines retrieved, by source. 
SOURCE RECALL REASONS FOR EXCLUSION YIELD (%)
G-I-N database 1 -- 1 (100)
National Guidelines Clearinghouse 12 8 Not specific to Huntington’s
3 Not relevant
1 (8.3)
Orphanet 5 4 Not English language 1 (20)
Eurogentest 65 64 Not relevant 1 (1.5)
PubMed 34 1 Not English language
29 Not relevant
4 (11.8)
Evidence Search (NICE) 52 Not relevant 0 (0)
Google pdf  first 100 -- 93 Not relevant 7 (7)
Pearl growing -- -- 6
Total 169 De-duplication 11 (6.5)
Table 3. Costello syndrome guidelines retrieved, by source. 
SOURCE RECALL REASONS FOR EXCLUSION YIELD (%)
G-I-N database 1 Not English language 0 (0)
National Guidelines Clearinghouse 6 Not relevant 0 (0)
Orphanet 2 Not English language 0 (0)
Eurogentest 1 Not relevant 0 (0)
PubMed 1 Not relevant 0 (0)
Evidence Search (NICE) 53 Not relevant 0 (0)
Google pdf  first 100 -- 99 Not relevant
1 Not a guideline
0 (0)
Pearl growing -- -- 0 
Total 64 De-duplication 0 (0)
Table 4. Comparison of  three existing databases containing rare disease guidelines.
COMPARISON CRITERIA G-I-N 
(WWW.G-I-N.NET)
NGC 
(GUIDELINE.GOV)
ORPHANET 
(WWW.ORPHA.
NET)
Access Login required 
(limited free access)
Free access and free registration Free access
Collections policy Guideline documents 
produced by G-I-N 
members
Guidelines produced by specified types of  
formal organisations, in English, in the past 
five years, based on a systematic review 
of  evidence and contain an assessment of  
benefits and harms
“summary 
recommendations 
for the management 
of  patients, 
issued by official 
organisations”
Content development G-I-N members NGC searches and user suggestions INSERM
Language Multiple English only Multiple
Number of  guideline records 6516 >2600 unknown
Document information Bibliographic record, 
MeSH terms
Detailed information on guideline scope, 
methods, recommendations, supporting 
evidence
Hyperlink to 
document only
Quality assessment provided No No No
Additional features None ‘Compare guideline’ function, personalisation, 
topic alerts
‘Search by sign’ 
function
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Comparison of  guideline databases
In order to determine whether resources already existed with the same proposed scope and focus as the RARE-
Bestpractices database, we included in the comparison only databases that were publicly available, international in 
scope, and inclusive of  the full spectrum of  diseases (i.e. not limited to a specific disease area, e.g. cancer). On this basis, 
we identified two international databases of  clinical guidelines and the Orphanet collection of  information on rare dis-
eases for inclusion. We compared these three sources using eight criteria to determine whether there were any potential 
gaps in coverage of  RD or in the information provided about the included guidelines. Table 4 presents the characteristics 
of  the existing guideline databases.
The G-I-N database (accessible at http://www.g-i-n.net/library) currently contains 6516 records of  guidelines which 
have been produced by G-I-N members and which are published in many languages. Only details of  the title and pub-
lisher of  these guidelines is publicly available with further details accessible only to G-I-N members. Many of  these 
guidelines will be freely available but will require further searching by non G-I-N member users via individual publishers’ 
websites. The collection includes guidelines for common and rare diseases.
NGC is hosted by the US Department of  Health and Human Services (http://www.guideline.gov). At present, for 
inclusion in the database, guidelines must be developed by “medical specialty associations; relevant professional societ-
ies, public or private organizations, government agencies at the Federal, State, or local level; or health care organizations 
or plans”. The inclusion criteria also now require guidelines to meet rigorous quality standards relating to systematic 
review, evidence synthesis, and appraisal of  benefits and harms. The size of  the collection is not described but we esti-
mate there are over 2600 guidance documents available. Both common and rare conditions are included in the collection. 
The guideline development methodology, a detailed synopsis and list of  recommendations together with links to the 
publisher’s website are provided in the database record.
Orphanet (www.orpha.net) covers almost 6000 rare diseases with information provided ranging from disease sum-
maries and expert centres to guidelines and other treatment information.  It is not possible to search for guidelines only 
but disease entries within the Orphanet Professional Encyclopaedia contain some direct links to guideline documents.
Comparison of  research recommendation databases
There has been a much smaller number of  initiatives to develop collections of  research recommendations arising 
from gaps in the current evidence base than there are collections of  guidelines. The databases considered in detail here 
are UK based, although we are aware of  one being established in Sweden based on the UK DUETS database described 
below and other initiatives in Canada and Spain (personal communication). We have not identified any databases of  
research recommendations arising from international collaborations; however, international groups who have identified 
research recommendations have approached UK DUETS to use their quality assurance processes to verify uncertainties 
and include the uncertainties in UK DUETS. We found no databases specifically collating research questions on rare 
diseases.
The UK Database of  Uncertainties of  the Effects of  Treatment (UK DUETS) was established in 2005 by the NHS 
in England and since 2010 has been hosted within NICE Evidence Services (http://www.library.nhs.uk/duets/). The col-
lection comprises research questions arising from a range of  sources including research uncertainties from surveys of  
patients, carers and professionals; research recommendations arising from evidence updates, guidelines and relevant and 
reliable systematic reviews; and ongoing primary and secondary research activity. Information on the recommendations 
includes: the source of  the question; the citation to any relevant and reliable systematic review; systematic reviews which 
might if  extended address the uncertainty if  updated; the type of  response required to address the uncertainty; and any 
ongoing research that might address the uncertainty. The date of  review of  the question is provided, but the process for 
question review and updating is not clear.
NICE hosts a separate database of  research recommendations arising specifically from NICE products, such as 
guidelines, single interventional procedures, diagnostic reviews, technology assessments and guidelines from public 
health and social care. Information contained within the records includes the source of  the question and its level of  pri-
ority. Prioritisation of  research recommendations is led by advisory groups developing the guideline or other output and 
a systematic approach to undertake this prioritisation process is defined in the published guide for developing research 
recommendations.
The UK DUETS database and NICE research recommendations databases use the EPICOT format to structure 
records of  uncertainties and research questions. [24] This format comprises the following elements:
• What comprises the Evidence?
• What is the Population of  interest?
• What are the Interventions of  interest?
• What are the Comparisons of  interest?
• What are the Outcomes of  interest?
• Time stamp (date of  recommendations).
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The EPICOT format provides a structure for the formulation of  research questions and has been recommended to 
avoid authors listing general or vague questions that make implementation problematic and provides an indication of  the 
state of  the evidence base at the time of  original formulation.
Working closely with DUETS is the James Lind Alliance (JLA) (www.lindalliance.org/), established in 2004, and 
recently transferred to the UK National Institute of  Health Research. This organisation facilitates patient and clinician 
groups, Priority Setting Partnerships, to identify uncertainties and then prioritise the research into treatment effects of  
greatest importance to them. The JLA process uses a range of  methods of  identifying areas of  uncertainty including the 
use of  surveys amongst patient and clinical populations as well as identification from the existing literature. Submitted 
uncertainties are included in the database in fields indicating the population, intervention, comparator and outcome 
(PICO) format and verified against sources such as the Cochrane Library, NICE and SIGN guidelines before being in-
cluded in the prioritisation phase.  A transparent method of  achieving consensus as to the top 10 priorities in a particular 
topic area is then undertaken. Where identified uncertainties, e.g. regarding natural history of  disease or communication 
approaches, are not suitable for inclusion in DUETS, Priority Setting Partnerships are encouraged to forward these to 
relevant organisations who can consider these within their own processes.
DISCUSSION
It was noteworthy that, for the three sample topics searched, only one of  the documents retrieved and confirmed 
as a guideline was recorded in the two largest international databases, G-I-N and NGC. A possible explanation for this 
omission is that RD guidelines are often developed by small specialist groups which may not be aware of  such dissemina-
tion facilities or have the resource to submit their guidelines to them. For example, a key guidance document for Turner 
Syndrome(9) was developed by a multidisciplinary panel of  experts brought specifically to work on this publication. As 
such they may not qualify or may not wish to become G-I-N members and so would not be able to add their guideline to 
the database. Previous research has established that guidelines developed by professional societies or specialist groups 
are generally of  lower methodological quality than guidelines developed by governmental bodies [25]. The NGC inclusion 
criteria relating to rigour of  systematic review and evidence synthesis may therefore constitute a further barrier to the 
dissemination of  RD guidelines.
Similarly, only one of  the guidelines retrieved by our search was recorded in Orphanet. However, Orphanet did 
contain links to other references that would facilitate pearl growing, and additional records of  non-English guidelines for 
each of  the sample topics. The entry for Costello syndrome, for example, provides access to Spanish and French language 
guidelines [26,27] which were excluded by limiting our scoping search to English language documents. This demonstrates 
the importance of  removing language restrictions in searching for RD guidelines, but also indicates a potential barrier to 
the dissemination and implementation of  recommendations. Systematic reviewers of  RD guidelines should be adequate-
ly resourced for translation. Funding bodies may wish to compare the cost of  translating and adapting a good-quality 
guideline from another language with the cost of  producing a de novo guideline.
The credibility of  general purpose search engines to retrieve reliable and comprehensive coverage of  health informa-
tion has previously been brought into question [28]. However, more recent research has shown Google Scholar to be as, 
if  not more, effective as PubMed at identifying health literature [29]. The results from our test searches indicate that 
Google is indeed an effective resource to locate RD guidelines, identifying nearly all of  the retrieved guidelines in the first 
100 results. Limiting to PDF document type appeared to be successful in improving specificity, given that most guideline 
documents published on the web are in this format. Also, the PDF documents are generally immediately available to 
view, and so reduce time and resource spent trying to access full text documents. 
Previous research has demonstrated that, when searching for health-related information, internet users seldom read 
beyond the second page of  results [30] and that both doctors and nurses report lack of  time and lack of  search skills as 
barriers to accessing online information [31]. Although the Google search results were limited to the first 100 results for 
practical reasons, the yield remained very low for all conditions and, despite using guideline terms in the search strategy, 
there were many irrelevant results. Thus, there is scope for a database tailored to RD guidelines to reduce the time and 
effort required to locate disease guidelines by allowing for more precise searches and a high yield of  relevant results.
It is recognised that guidance documents may also be published in subscription-only resources and therefore might 
be excluded from the Google search by way of  document type. In our three chosen examples this proved not to be the 
case as the PubMed search failed to identify any unique citations.
Huntington’s Disease offers an example in which methods such as pearl growing may be useful in the location of  RD 
guidelines. The journal in which six guidelines were published in 2012 by the European Huntington’s Disease Network, 
Neurodegenerative Disease Management, is not indexed for Medline, meaning that these guidelines could not be retrieved 
via PubMed. Nor were five of  these six guidelines obtained by the Google search strategy, which on analysis appeared to 
be the result of  a metadata issue within the documents. Instead, references provided in the one retrieved guideline led to 
the identification of  the other five.
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In general, compared to our experiences in searching for guidelines on common diseases, we observed relatively 
low recall, very low yield, and very little duplication across sources. A larger proportion of  guidelines addressed ge-
netic testing, laboratory testing, and diagnosis. Guidelines were more likely to focus on a specific aspect of  diagnosis 
or treatment (e.g. management of  a specific symptom) and not to cover the full pathway of  care.
The number of  results would have been much greater had guidelines been included that were not specifically 
about the named diseases but that included these diseases within broader clinical topics. For example, guidelines on 
dementias or movement disorders may address in part, or be relevant to, Huntington’s Disease; Turner’s may be ad-
dressed in guidelines on growth hormone replacement, or growth failure in children; Costello syndrome is one of  the 
RASopathies, a group of  nine syndromes with some overlap in phenotypes. Using broader search terms and including 
guidelines from related diseases would present different challenges for information retrieval and applicability, com-
pared with conventional search practices for guidelines on common diseases.
Although G-I-N and NGC are the largest guideline databases of  which we are aware, they produced fewer rel-
evant search results for RD topics than Google, indicating that RD guidelines and guideline developers are not well 
represented in their content or collection development methods. The yield for Google, however, ranged from 4% to 7%, 
meaning that the number needed to read in order to identify relevant results would be high. There appears to be a role 
for a database that has high specificity and high yield for RD guidelines.
Although NGC provides detailed information about the methodology of  included guidelines, none of  the three 
resources provides any quality assessment of  guidelines. Information on guideline quality is important in deciding 
whether a guideline should be implemented or is suitable for adaptation. Such information could add value within a 
database of  RD guidelines.
We identified only two databases of  research recommendations, both hosted by NICE in the UK. Neither of  these 
databases included uncertainties relating to the treatment of  our three exemplar rare conditions, although uncertain-
ties relating to RD are not excluded from these databases. 
The James Lind Alliance is instrumental in ensuring research is of  relevance to patients and clinicians and is not 
dominated by the priorities of  researchers or industry. The method used to identify research priorities is based on the 
establishment of  Priority Setting Partnerships. The majority of  the established Partnerships have common diseases 
as their focus, although a Priority Setting Partnership for Lyme Disease published its research priorities in 2012. Un-
certainties and research recommendations within UK DUETS cite any relevant and reliable systematic reviews, with 
the research recommendations mostly being based on the findings from systematic reviews. However, the updating 
process varies by the source of  the record and submissions from individuals have not been reviewed since the original 
prioritisation meetings.
The records within the NICE database of  research recommendations are less likely to be complete; however, 
there is a structured process for updating the records when the original guidance undergoes review and as a result the 
recommendations are more likely to be current than some of  those within UK DUETS. There is overlap between the 
UK DUETS and NICE databases.
To be useful, research recommendations need to be sufficiently specific to allow a study to be defined. Despite 
attempts to ensure that records follows the EPICOT format, records within the UK DUETS database may not have 
these characteristics, such as the Dementia Priority Setting Partnership recommendation “what are the best ways to 
care for people from ethnic minority groups with dementia in all care settings?”. 
In the development of  the RARE-Bestpractices database of  research recommendations further issues need to be 
considered, including the inclusion of  research recommendations of  importance to clinicians, patients and carers and 
whether a process of  prioritisation could be incorporated. We anticipate working closely with experienced teams such 
as those at NICE, UK DUETS and others to explore these issues. 
This study is, to our knowledge, the first to test existing search protocols and resources in order to determine 
their usefulness and limitations in identifying RD guidelines and research recommendations. It demonstrates that RD 
guidelines and research recommendations may not be well represented in existing databases and provides evidence 
that unconventional search techniques may perform better in identifying RD guidelines. The study was conducted as 
a scoping activity and thus does not reflect a formal systematic review on any of  the three selected RD topics, nor did 
it systematically search for research recommendations databases. Restricting the searches to English language docu-
ments clearly limited the retrieval of  RD guidelines; future systematic reviews of  RD guidelines should consider the 
potential impact of  language restrictions on selection bias.  
CONCLUSIONS
The results of  our scoping work and test searches demonstrate that existing resources do not allow for rapid or 
complete identification of  relevant RD guidelines and research recommendations, and that dedicated RD resources, 
tools and methods are therefore necessary. In a climate of  scarce resources for RD guideline development and dis-
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semination, and given evidence of  gaps in RD coverage in existing guideline databases, the creation of  new data-
bases dedicated to RD guidelines and research recommendations is called for. The new guidelines database developed 
within the RARE-Bestpractices project is intended to meet the needs of  multiple stakeholders. Clinicians, patients 
and policymakers will be able to quickly and easily identify relevant guidelines on specific topics without needing to 
navigate complex interfaces or conduct difficult searches. Guideline developers will be able to demonstrate the need 
for a particular guideline to funding bodies by demonstrating gaps in current guideline coverage, scope, or quality as 
recorded in the database. Researchers will be able to use the database to investigate the translation of  evidence into 
guidelines, for example, or for epidemiological research into guideline coverage and quality. Similarly, a research rec-
ommendations database will ensure that RD guideline developers, researchers and patient organisations have access 
to a well-designed platform for disseminating these recommendations. Development of  these resources will also entail 
the further development and testing of  effective and innovative search strategies for RD guidelines. Dedicating these 
resources to RD will help to address the inequality that is potentially exacerbated where higher-prevalence disease 
guidelines and research recommendations are better resourced, better disseminated and more easily retrieved.
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